ArticleFrontiers in cell and developmental biology2026
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) remains a major cause of cancer-related mortality, and the molecular drivers underlying GC progression require further clarification. SLC12A7 has been implicated in several malignancies, but its clinical significance and biological function in GC remain incompletely understood. Objective: To investigate the clinical significance and functional role of SLC12A7 in GC and to explore whether Ezrin-associated PI3K/AKT signaling is involved in SLC12A7-mediated malignant phenotypes. Methods: TCGA-STAD RNA-seq data, GEO datasets (GSE29272, GSE3438, and GSE66229), and tissue microarrays were integrated to evaluate SLC12A7 expression and its clinicopathological relevance in Gastric cancer. STRING analysis, molecular docking, and immunofluorescence colocalization were used to assess the potential association between SLC12A7 and Ezrin. Functional assays, including siRNA-mediated knockdown, Ezrin re-expression, CCK-8, Transwell, flow cytometry, qRT-PCR, and Western blotting, were performed to examine proliferation, migration, invasion, cell-cycle distribution, apoptosis, EMT-associated markers, and PI3K/AKT signaling in GC cells. Results: SLC12A7 was upregulated in GC tissues and cell lines and was associated with selected clinicopathological characteristics and shorter survival. Conclusion:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.